Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H.

Nature. 2007 Aug 2;448(7153):561-6. Epub 2007 Jul 11.

PMID:
17625570
2.

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H.

Cancer Res. 2008 Jul 1;68(13):4971-6. doi: 10.1158/0008-5472.CAN-07-6158.

3.

Cancer: broken genes in solid tumours.

Meyerson M.

Nature. 2007 Aug 2;448(7153):545-6. No abstract available.

PMID:
17671492
5.

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y.

J Thorac Oncol. 2008 Jan;3(1):13-7. doi: 10.1097/JTO.0b013e31815e8b60.

6.

Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics.

Radtke J, Rezaie SG, Kugler Ch, Zabel P, Schultz H, Vollmer E, Goldmann T, Lang DS.

Rom J Morphol Embryol. 2010;51(4):647-53.

7.

Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.

Mano H.

Cancer Sci. 2008 Dec;99(12):2349-55. doi: 10.1111/j.1349-7006.2008.00972.x. Epub 2008 Nov 20. Review.

8.

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M; University of Hong Kong Lung Cancer Study Group.

Cancer. 2009 Apr 15;115(8):1723-33. doi: 10.1002/cncr.24181.

9.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
10.

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.

Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, Carbone A, Fabbri A, Sidoni A, Nakamura S, Gambacorta M, Fernández PL, Ramirez J, Chan JK, Grigioni WF, Campo E, Pileri SA, Falini B.

Am J Pathol. 2009 Feb;174(2):661-70. doi: 10.2353/ajpath.2009.080755. Epub 2009 Jan 15.

11.

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z.

Mol Cancer Res. 2009 Sep;7(9):1466-76. doi: 10.1158/1541-7786.MCR-08-0522. Epub 2009 Sep 8.

12.
13.

[A new target in non-small cell lung cancer: EML4-ALK fusion gene].

Wang H, Yuan J, Ma Z.

Zhongguo Fei Ai Za Zhi. 2011 Jun;14(6):538-42. doi: 10.3779/j.issn.1009-3419.2011.06.11. Review. Chinese.

14.

[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].

Zeng Z, Wu Y.

Zhongguo Fei Ai Za Zhi. 2011 Nov;14(11):880-4. doi: 10.3779/j.issn.1009-3419.2011.11.09. Review. Chinese.

15.

Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.

Toyokawa G, Seto T.

Respir Investig. 2014 Nov;52(6):330-8. doi: 10.1016/j.resinv.2014.06.005. Epub 2014 Jul 30. Review.

PMID:
25453376
16.
17.

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, Wang X, Peterson LM, Halling KC, Oliveira AM, Aubry MC, Yi ES.

Hum Pathol. 2009 Aug;40(8):1152-8. doi: 10.1016/j.humpath.2009.01.012. Epub 2009 Apr 22.

PMID:
19386350
18.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, McDougall J, Wylie AA, Robison K, Caliri K, Palombella VJ, Fritz CC.

Oncogene. 2011 Jun 2;30(22):2581-6. doi: 10.1038/onc.2010.625. Epub 2011 Jan 24.

PMID:
21258415
19.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.

Okamoto I, Nakagawa K.

Cancer Sci. 2012 Aug;103(8):1391-6. doi: 10.1111/j.1349-7006.2012.02327.x. Epub 2012 Jun 17. Review.

20.

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, Sammarelli G, Thai E, Ardizzoni A.

Lung Cancer. 2011 Feb;71(2):241-3. doi: 10.1016/j.lungcan.2010.11.014. Epub 2010 Dec 18.

PMID:
21168933

Supplemental Content

Support Center